Trial of Psilocybin versus Escitalopram for Depression
Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking.
Science & Research
Comparative Efficacy of Racemic Ketamine and Esketamine for Depression
Intravenous ketamine appears to be more efficacious than intranasal esketamine for the treatment of depression.
Antidepressant Actions of Ketamine Engage Cell-Specific Translation via eIF4E
Sub-anaesthetic doses of ketamine, a noncompetitive N-methyl-d-aspartate receptor antagonist provide rapid and long-lasting antidepressant effects in these patients, but the molecular mechanism of these effects remains unclear.
Ketamine Can Reduce Harmful Drinking by “Rewriting” Your Memories
Maladaptive reward memories (MRMs) are involved in the development and maintenance of acquired overconsumption disorders, such as harmful alcohol and drug use. Here we demonstrate that the N-methyl D-aspartate (NMDA) antagonist ketamine is able to disrupt MRMs in hazardous drinkers when administered immediately after their retrieval.
Ketamine for Unipolar and Bipolar Depression
Due to unmet clinical needs for efficient drugs with a rapid onset of antidepressant effects, we aimed to evaluate the efficacy of single-dose ketamine in different subgroups of patients with major depression and establish whether repeated ketamine administration could be a viable strategy to maintain treatment gains.
Psychedelic Psychiatry’s Brave New World
After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results.
NAD+ in Aging: What It Is & Why You Need It
Rhonda Patrick explains what NAD+, why it is so important for aging and why it declines with age. She discusses some of the popular NAD+ boosters like nicotinamide riboside and nicotinamide mononucleotide, what animal and human data says and some concluding thoughts.
Study: Ketamine for Chronic Posttraumatic Stress Disorder (PTSD)
The authors’ previous proof of- concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion.
NAD+ Boosters: How They Slow Aging
Rhonda Patrick explains what NAD+, why it is so important for aging and why it declines with age. She discusses some of the popular NAD+ boosters like nicotinamide riboside and nicotinamide mononucleotide, what animal and human data says and some concluding thoughts.
Ketamine Isn’t an Opioid, and it Treats Depression in a Unique Way
Ketamine has gotten a bad rap as an opioid when there’s plenty of evidence suggesting it isn’t one, Johns Hopkins experts say. They believe this reputation may hamper patients from getting necessary treatment for the kinds of depression that don’t respond to typical antidepressants.